These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21397755)

  • 41. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
    Hernandez RK; Farwell W; Cantor MD; Lawler EV
    J Am Geriatr Soc; 2009 Nov; 57(11):1997-2003. PubMed ID: 19793162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivastigmine associated hyponatremia in an older patient with Alzheimer's disease.
    Naharci IM; Bozoglu E; Karadurmus N; Karaman M; Kurt O; Doruk H
    J Am Geriatr Soc; 2011 Jul; 59(7):1351-2. PubMed ID: 21751972
    [No Abstract]   [Full Text] [Related]  

  • 44. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia.
    Alwahhabi FK
    J Psychopharmacol; 2005 Mar; 19(2):214-6. PubMed ID: 15728444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
    Dautzenberg PL; Wouters CJ; Oudejans I; Samson MM
    Int J Geriatr Psychiatry; 2003 Jun; 18(6):555-6. PubMed ID: 12789683
    [No Abstract]   [Full Text] [Related]  

  • 47. [Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment].
    Olde Rikkert MG; Jansen RW
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2644; author reply 2645. PubMed ID: 10028367
    [No Abstract]   [Full Text] [Related]  

  • 48. A picturesque reversal of antimuscarinic delirium.
    Richardson WH; Williams SR; Carstairs SD
    J Emerg Med; 2004 May; 26(4):463. PubMed ID: 15093860
    [No Abstract]   [Full Text] [Related]  

  • 49. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.
    Dautzenberg PL; Mulder LJ; Olde Rikkert MG; Wouters CJ; Loonen AJ
    Int J Geriatr Psychiatry; 2004 Jul; 19(7):641-4. PubMed ID: 15254920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of cholinesterase inhibitor therapy initiation among hospitalized patients.
    Swan JT; Wagle KC; Thompson-Moore N; Taffet GE
    J Hosp Med; 2013 Jun; 8(6):304-8. PubMed ID: 23526817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strategies to improve tolerability of rivastigmine: a case series.
    Venkatesh K; Bullock R; Akbaş A
    Curr Med Res Opin; 2007 Jan; 23(1):93-5. PubMed ID: 17257470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review for usefulness of atypical antipsychotics and cholinesterase inhibitors in delirium.
    Tahir TA
    Pharmacopsychiatry; 2012 Jun; 45(4):163; author reply 164. PubMed ID: 22174027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.
    Logan CJ; Stewart JT
    J ECT; 2007 Mar; 23(1):28-9. PubMed ID: 17435571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Study of rivastigmine for delirium in intensive care is stopped after deaths.
    Sheldon T
    BMJ; 2010 May; 340():c2895. PubMed ID: 20511318
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
    Olin JT; Bhatnagar V; Reyes P; Koumaras B; Meng X; Brannan S
    Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization.
    Makris M; Koulouris S; Koti I; Aggelides X; Kalogeromitros D
    Allergy; 2010 Jul; 65(7):925-6. PubMed ID: 19889118
    [No Abstract]   [Full Text] [Related]  

  • 58. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unsubstantiated superiority claims for rivastigmine tartrate.
    Shah SK; Krueger PM
    J Am Osteopath Assoc; 2006 Oct; 106(10):589-90; author reply 590. PubMed ID: 17122027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.